Page 90 | Certara

White Paper

Understanding the Impact of FDA Modernization Act 2.0 on Drug Development

Learn how the FDA Modernization Act 2.0 will change the drug development landscape by allowing…

CertaraJuly 6, 2023

On-Demand Webinar

How QSP brings insights and accelerates bispecific antibody drug development

Wednesday, August 9th 2023 More than 50 bispecific antibodies are in oncology clinical development with…

CertaraJune 29, 2023

On-Demand Webinar

Quantitative Systems Pharmacology (QSP) Model Applications in Inflammatory Bowel Disease (IBD) and Alzheimer’s Disease

Meet the Quantitative Systems Pharmacology (QSP) experts and view applications in Inflammatory Bowel Disease (IBD)…

CertaraJune 29, 2023

On-Demand Webinar

Project Optimus: Transforming oncology drug development

CertaraJune 29, 2023

Publication

Interlaboratory Variability in the Madin–Darby Canine Kidney Cell Proteome

Madin–Darby canine kidney (MDCK) cells are widely used to study epithelial cell functionality. Their low…

CertaraJune 28, 2023

Poster

The Usefulness of Combining Clinical Therapeutic Drug Monitoring Data with Bottom-up System Data to Understand the Effect of Renal Impairment on the Non-renal Clearance of Drugs: Tacrolimus as a Drug Example

CertaraJune 28, 2023

On-Demand Webinar

Applying Technology to Expedite Regulatory Writing

Many medical writing capabilities and approaches have matured over the past several years opening the…

CertaraJune 25, 2023

On-Demand Webinar

GlobalSubmit Review and You: How to Expedite the Submission Review Process

Have you ever wondered how you could speed up the submission review process without compromising…

CertaraJune 25, 2023

Announcement

DIDB^® – The Drug Interaction Database, is now part of Certara

PRINCETON, N.J.— June 20, 2023 — Certara, Inc. (Nasdaq: CERT), today announced it has acquired…

CertaraJune 21, 2023

Publication

Model-Informed Approaches and Innovative Clinical Trial Design for Adeno-Associated Viral Vector-Based Gene Therapy Product Development: A White Paper

The promise of viral vector-based gene therapy (GT) as a transformative paradigm for treating severely…

CertaraJune 14, 2023

Understanding the Impact of FDA Modernization Act 2.0 on Drug Development

How QSP brings insights and accelerates bispecific antibody drug development

Quantitative Systems Pharmacology (QSP) Model Applications in Inflammatory Bowel Disease (IBD) and Alzheimer’s Disease

Project Optimus: Transforming oncology drug development

Interlaboratory Variability in the Madin–Darby Canine Kidney Cell Proteome

The Usefulness of Combining Clinical Therapeutic Drug Monitoring Data with Bottom-up System Data to Understand the Effect of Renal Impairment on the Non-renal Clearance of Drugs: Tacrolimus as a Drug Example

Applying Technology to Expedite Regulatory Writing

GlobalSubmit Review and You: How to Expedite the Submission Review Process

DIDB^® – The Drug Interaction Database, is now part of Certara

Model-Informed Approaches and Innovative Clinical Trial Design for Adeno-Associated Viral Vector-Based Gene Therapy Product Development: A White Paper

Newsletter sign up

Quick links

Solutions

Contact